Novartis Reports Long-Term Efficacy for Ianalumab in Sjögren’s Disease Patients
Novartis (NVS) has released long-term clinical data from its NEPTUNUS extension study regarding ianalumab, a candidate treatment for Sjögren’s disease. The results indicate that patients receiving a monthly 300 mg dose of ianalumab experienced sustained improvements in systemic disease activity through week 108 of the treatment period. The findings suggest potential long-term efficacy and stability for the drug in managing symptoms associated with this autoimmune condition. This data provides critical evidence for the clinical development path of ianalumab as Novartis seeks to address unmet needs in the Sjögren’s disease market.
Tickers: $NVS